Form SC 13G/A GALAPAGOS NV Filed by: FMR LLC
Galapagos NV - American Depositary Shares (GLPG)
Last galapagos nv - american depositary shares earnings: 10/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
glpg.com/company-overview
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
GLPG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLPG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLPG alerts
High impacting Galapagos NV - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GLPG
News
- Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma [Yahoo! Finance]Yahoo! Finance
- Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin LymphomaGlobeNewswire
- Galapagos NV (NASDAQ: GLPG) was downgraded by analysts at Kepler Capital Markets from a "hold" rating to a "reduce" rating.MarketBeat
- Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024GlobeNewswire
- Galapagos NV (NASDAQ: GLPG) had its price target lowered by analysts at Royal Bank of Canada from $32.00 to $30.00. They now have a "sector perform" rating on the stock.MarketBeat
GLPG
Earnings
- 5/2/24 - Beat
GLPG
Sec Filings
- 12/9/24 - Form 6-K
- 11/20/24 - Form S-8
- 11/6/24 - Form 6-K
- GLPG's page on the SEC website